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Summary 
 Acute inflammation is triggered by a variety of cellular stresses and leads among other 
things to the activation of the nuclear transcription factor kappa B (NF-κB). NF-κB belongs to 
a family of inducible transcription factors and plays a crucial role in the regulation of many 
genes involved in mammalian immune and inflammatory response, including cytokines, cell 
adhesion molecules, complement factors, and a variety of immune receptors. It was shown, 
that several transcriptional co-factors are involved in the expression of NF-κB target genes. 
Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme converting NAD+ into 
poly(ADP-ribose) polymers which are attached to PARP1 itself or other proteins. A 
pathophysiological role of PARP1 has been demonstrated in a number of diseases and animal 
models, including LPS-induced septic shock. Recently our laboratory provided strong 
evidence that PARP1 acts as transcriptional co-factor in NF-κB transcriptional activation. 
 The aim of this thesis was to shed light on the physiological role of PARP1 as 
transcriptional co-factor for NF-κB-dependent gene expression during the cell cycle. 
 RAW 267.4 macrophages were transduced with a retrovirus expressing either a 
shPARP1 or a shMock RNA construct to stably knockdown PARP1 protein levels. Gene 
expression analyses of several LPS-induced NF-κB-target genes in these cell lines revealed 
that PARP1 has a dual function. PARP1 acts as co-repressor for Csf2, IL-1b and IL-12 gene 
expression which is not influenced by cell cycle synchronization. Interestingly, PARP1 acts in 
unsynchronized cells for the IP-10 gene expression as transcriptional co-activator, but as co-
repressor in early S phase (Thymidine or Aphidicolin treated cells). In contrast, PARP1 acts 
in unsynchronized cells for Mpa2l gene expression as co-repressor, but as co-activator during 
S phase (cells treated with Thymidine and release). Finally, in unsynchronized cells, gene 
expression for Lif is PARP1 independent, while after Thymidine (early S phase) and 
Nodocazol (G2/M) treatment PARP1 acts as co-activator, thus providing evidence that 
PARP1 can indeed change its function during the cell cycle. 
 Together our results provide strong evidence for the involvement of PARP1 in NF-
κB-dependent gene expression during the cell cycle, although the mechanisms regulating 
these processes have to be further elucidated. A better understanding of the NF-κB 
physiology and of factors influencing the expression of NF-κB target genes is of great 
importance, since NF-κB has been implicated in different cellular processes and in a broad 
range of diseases, one example being LPS induced septic shock. 
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Zusammenfassung 
Eine akute Entzündung kann durch eine Vielzahl von zellulären Stresssituationen ausgelöst 
werden und führt unter anderem zur Aktivierung des nukleären Transkriptionsfaktors kappa B 
(NF-κB). NF-κB gehört zu einer Familie von induzierbaren Transkriptionsfaktoren und spielt 
eine entscheidende Rolle in der Genregulation von Immun- und Entzündungsreaktionen. 
Insbesondere die Regulierung von Cytokinen , Zelladhesionsmolekülen, Komplementfaktoren 
und von etlichen Immunrezeptoren ist von NF-κB reguliert. Poly(ADP-ribose) Polymerase 1 
(PARP1) ist ein nukleäres Enzym, welches NAD+ zu Poly(ADP-ribose) Polymeren 
umwandelt, die sich dann an PARP1 selber oder an andere Proteine anlagern. PARP1 wurde 
eine pathophysiologische Rolle in mehreren Krankheits- und Tiermodellen zugeschrieben, 
wie zum Beispiel bei LPS induziertem septischem Schock. PARP1 besitzt eine von den vielen 
transkriptionellen Kofaktorfunktionen im NF-κB Signalweg. 
 Das Ziel dieser Dissertation war es, die physiologische Rolle von PARP1 als 
transkriptioneller Kofaktor in der Genexpression während des NF-κB Signalweges in 
Abhängigkeit vom Zellzyklus besser zu verstehen. 
 RAW 267.4 Makrophagen wurden mit einem Retrovirus, welcher entweder ein 
shPARP1 oder ein shMock RNA Konstrukt exprimiert, transduziert, um die PARP1 Protein 
Levels entscheidend herabzusetzten. Zellzyklus abhängige Untersuchungen von 
verschiedenen LPS induzierten NF-κB Zielgenen in asynchronen Zellen zeigen eine 
“Doppelfunktion” für PARP1. Unabhängig vom Zellzyklus ist PARP1 ein Korepressor für IL-
1b, Csf2 und IL-12. Interessanterweise ist für die Genexpression von IP-10 PARP1 ein 
Koactivator in asynchronene Zellen, aber in der frühen S Phase (mit Thymidin oder 
Aphidicolin behandelte Zellen) agiert PARP1 als Korepressor. Gegenteilig dazu agiert 
PARP1 während der Genexpression von Mpa2l als Korepressor in asynchronene Zellen, aber 
während der S Phase (Zellen behandelt mit Thymidin und Release) spielt PARP1 eine 
Koactivator Rolle. Für Lif ist die Genexpression in asynchronen Zellen unabhänging von 
PARP1, jedoch zeigt sich für Zellen mit einer Thymidin (frühe S Phase) Behandlung und 
einer Nocodazol (G2/M Phase) Behandlung eine Koaktivator Funktion für PARP1. Diese 
Daten deuten sehr darauf hin, dass PARP1 seine Funktion während des Zellzyklus ändern 
kann. 
 Zusammengefasst liefern uns diese Resultate einen eindeutigen Hinweis, dass PARP1 
eine zellzyklus abhängige regulatorische Aktivität im NF-κB Signalweg besitzt. Um den 
exakten Regulationsmechanismus zu verstehen, sind jedoch weitere Studien nötig. Ein 
besseres Verständnis der NF-κB Physiologie und der beteiligten Kofaktoren, welche die 
Expression von NF-κB Zielgenen beeinflussen, ist von grosser Bedeutung, da NF-κB bei 
vielen Krankheitsmechanismen beteiligt ist, wie zum Beispiel bei LPS induziertem 
septischem Schock. 
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Abbreviations 
ADP Adenosine diphosphate 
AIF Apoptosis inducing factor 
AMD Auto modification domain 
ARD Ankyrin repeat domain 
ATP Adenosine triphosphate 
BRCT BRCA1 C-terminus 
CDK Cyclin dependent kinase 
C-terminus Carboxy terminus 
DBD DNA binding domain 
DNA Deoxyribonucleic acid 
DSB Double strand break 
FACS Fluorescence activated cell sorting 
H1 Histone 1 
H2B Histone 2B 
IκB Inhibitor κB 
IKK IκB kinase 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
LPS Lipopolysaccharide 
LZ Leucin zipper 
MAPK Mitogen-activated protein kinase 
MEF Mouse embryonic fibroblast 
NAD Nicotinamide adenine dinucleotide 
NF-κB Nuclear transcription factor κB 
NLS Nuclear localization signal 
N-terminal Amino terminus 
p53 Tumor protein 53 
PAMPs Pathogen-associated molecular patterns 
PAR Poly(ADP-ribose) polymer 
PARG Poly(ADP-ribose) glycohydrolase 
PARP Poly(ADP-ribose) polymerase 
PARP1(-/-) PARP1 knockout 
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PBS Phosphate bufferd saline 
PI Propidium iodid 
RNA Ribonucleic acid 
SDS Sodium-dodecyl-sulfate 
SSB Single strand break 
TBS Tris bufferd saline 
TBS-T Tris bufferd saline Tween 20 
TLR Toll like receptor 
TNFα Tumor necrosis factor α 
ZF Zinc finger 
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1 Introduction 
1.1 Nuclear factor kappa B (NF-κB) 
1.1.1 Introduction 
 Nuclear factor kappa B (NF-κB) belongs to a family of inducible transcription factors 
and regulates gene expression in response to a variety of extracellular and intracellular stimuli 
(1). NF-κB was initially identified as a biochemical protein capable of binding to a 10 base 
pairs (bp) sequence within the transcriptional enhancer of the immunoglobulin (Ig) κ light 
chain gene in B cells (2). NF-κB plays a crucial role in the regulation of many genes involved 
in mammalian immune and inflammatory response, including cytokines, cell adhesion 
molecules, complement factors, and a variety of immune receptors (2). It has additionally 
been implicated as an important regulator of cellular processes such as apoptosis, cell 
proliferation and differentiation (3). Furthermore, NF-κB plays important roles in a myriad of 
physiological and pathophysiological scenarios. 
 
1.1.2 The NF-κB family 
 The mammalian NF-κB family consists of five members; RelA (p65), RelB, c-rel, 
p105/p50 (NF-κB1) and p100/p52 (NF-κB2). NF-κB is composed of homo- and heterodimers 
formed by these subunits (4). The family members share a conserved 200-amino acid region 
within their amino termini, termed the Rel homology domain. This domain is responsible for 
DNA binding, dimerization, nuclear translocation, and interactions with heterologous 
transcription factors (5).  
 
1.1.3 NF-κB signalling pathway 
 In unstimulated cells, NF-κB is sequestered in the cytoplasm as an inactive 
transcription factor complex through physical association with one of the inhibitors of NF-κB 
(IκB). The family of IκBs includes IκBα, IκBβ, IκBγ, IκBε, p105/p50 (C terminus), 
P100/p52 (C terminus), IκB-R, and Bcl-3 (6, 7). Treatment of cells with extracellular stimuli, 
including cytokines such as IL-1 or TNFα, viral proteins, bacterial LPS, phorbal ester, UV 
and γ-irridiation or potent oxidants leads to the induction of NF-κB (2, 7). The key regulatory 
Introduction 
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event for the induction of NF-κB is the phosphorylation of the IκB proteins by the IκB kinase 
(IKK) complex, which leads to IκB protein ubiquitylation and subsequent degradation (8). 
This results in the release of cytoplasmic NF-κB complexes, which subsequently translocate 
to the nucleus where the NF-κB dimers bind to κB sites of target genes (Fig. 1).  
Figure 1: Relevant regulatory nodes in NF-κB signalling pathway. In the simplest model of NF-κB induction, an 
inflammatory stimulus activates signal transduction pathways that induce the activation of the IKK (inhibitor of 
NF-κB (IκB) kinase) complex. This results in the phosphorylation and ubiquitylation of IκB proteins and 
consequently their degradation by the proteasome. Released NF-κB dimers translocate to the nucleus and bind 
κB-sites in the promoters or enhancers of target genes, which leads to their transcription (8). 
 
 Two major signalling pathways have been described and characterized so far which 
result in the activation of NF-κB activities via distinct kinases and IκB proteins (9). The 
canonical pathway is induced largely by IκB kinase β (IKKβ), and targets the three canonical 
IκB proteins IκBα, IκBβ, IκBε. The non-canonical pathway is activated through IKKα, and 
utilizes the p52 precursor protein p100 (10), whose C-terminal ARD domains can function 
like an IκB protein to sequester NF-κB dimers in an active state (2). A third possibility is the 
IKK-independent “atypical” pathway of NF- κB induction, which is activated for example by 
DNA damages (5).  
 Remarkably, all IκB genes have been reported to be NF-κB target genes, providing a 
potential negative feedback loop (2). In recognition that these dynamic molecular interactions 
are critical for NF-κB signalling, the network of IKK, IκB and NF-κB proteins has been 
termed the NF-κB signalling mechanism (11). Indeed, NF-κB activation dynamics may be 
stimulus-specific (12) and can be regulated by critical mechanisms for the activation of 
stimulus-specific gene expression programs (2).  
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1.1.4 Regulation of the NF-κB transcriptional activity 
 As a central regulator of the transcriptional control of inflammatory genes, NF-κB 
function is not a steady-state or equilibrium phenomenon, but occurs in the context of highly 
dynamic signalling events. Indeed, the transient nature of gene expression is the basis for the 
resolution of inflammation. Molecular attenuation mechanisms that limit inflammatory 
signalling have therefore received great attention (13). Furthermore, NF-κB activities appear 
in the nucleus and on target genes with characteristic temporal profiles (2). Within this 
context, it is notable that NF-κB target genes show distinct temporal expression profiles (14). 
 Transcriptional control involves the coordinated function of many proteins, including 
DNA-bound transcription factors, co-activators and co-repressors in the context of 
nucleosomal chromatin. The formation of hetero- and homodimers of the five family 
members that are selectively regulated by IκB proteins is a primary source of transcriptional 
specificity. Specificity in transcriptional responses can, in part, be additionally provided 
through the combinatorial effects of transcription factors. However, there are additional 
factors that determine what constitutes an NF-κB-regulated gene for a given stimulus (2). 
Given the large number of proteins located in DNA regulatory sequences, protein-protein 
interactions are likely as important as transcription factor-DNA interactions in determining 
transcriptional specificity (2).  
 
1.1.5 Induction of the NF-κB pathway by LPS 
 Primary human macrophages are sentinels of the immune system. Following infection, 
circulating monocytes migrate from the peripheral blood to tissues where they differentiate 
into resident tissue macrophages. Recognition of pathogen associated molecular patterns 
(PAMPS), including gram negative bacterial LPS, results in activation of macrophages, 
leading to a plethora of biological responses required for shaping both the innate and adaptive 
arms of the immune response (4). These effects are mediated through the release of 
chemokines and cytokines such as tumour necrosis factor α (TNFα) and interleukin 1b (IL-
1b). However, excess release of these mediators can result in septic shock, multiple organ 
failure and acute respiratory distress syndrome (4). 
 When LPSs are present in the bloodstream, they are immediately captured by LPS-
binding protein and then transferred to their cognate cellular receptor complex composed of 
CD-14, MD-2, and toll-like receptor 4 (TLR-4) (15, 16). Binding of LPS to the CD-14/MD-
Introduction 
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2/TLR-4 receptor complex activates via TLR-4-associated MYD88 complexes a diverse set of 
signalling cascades including the TRAF6/TAK1/IKK-α/IKK-β-IκB-NF-κB pathway. In 
macrophages, NF-κB might subsequently upregulate in concert with different other co-
activators (e.g. PARP1) the expression of specific sets of pro-inflammatory mediators 
involved in the pathogenesis of inflammation such as cytokines (TNFα, MIF, IFN-γ) or 
interleukins (IL-1b, IL-6, and IL-8). The massive production and release of cytokines by 
macrophages might then in turn activate leucocytes and other inflammatory cells (1).  
 
1.2 Poly(ADP-ribose) polymerase 1 
1.2.1 Introduction 
 Mammalian poly(ADP-ribose) polymerase 1 (PARP1) is an abundant nuclear 
chromatin-associated protein. PARP1 catalyzes the transfer of ADP-ribose units from its 
substrate β-nicotinamide adenine dinucleotide (NAD+) covalently to itself and other nuclear 
proteins (1). PARP1 was identified by Pierre Chambon et al. in 1963 (17). Ubiquitous PARP 
activity has been found in organisms ranging from archaebacteria to mammals, although it is 
apparently absent in yeast (1). PARP1, a 113 kDa protein, is the prototypical and most 
abundantly expressed member of the PARP family (18).  
 
1.2.2 The PARP family 
 For a long time, the best-investigated PARP protein, PARP1, has been thought to be 
the only enzyme with poly(ADP-ribosyl)ation activity in mammalian cells. However, this 
view has been challenged by the development of mice deficient in PARP1 (19). Primary cells 
derived from PARP1 knockout (-/-) mice could still synthesize poly-ADP-ribose following 
treatment with DNA-damaging agents (20). The “PARP signature” from the catalytic domain 
(see 1.2.3) was used to search non-redundant protein databases from the National Center for 
Biotechnology Information (NCBI) for human PARP homologues. Subsequently, five new 
genes encoding “bona fida” PARP enzymes have been identified (21), indicating that PARP1 
belongs to a family of poly(ADP-ribose) polymerases (22). Later, additional putative PARPs 
were identified, which increased the number of PARP-family members to 17. It has however 
to be confirmed whether these proteins are “real” poly(ADP-ribose) polymerases or whether 
they have only mono(ADP-ribosyl) transferase activity (23). Noteworthy is PARP2, which 
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seems to be most closely related to PARP1 in terms of structure and function (21). Both 
proteins are nuclear proteins and were reported to play important roles in the cellular response 
toward stress (24). The functions of the other PARP family members appear to be quite 
diverse, but are less well characterized. 
 
1.2.3 Structure of PARP1  
 The structure of PARP1 has been extensively characterized (25). PARP1 is a highly 
conserved multifunctional enzyme consisting of three domains: a DNA-binding domain 
(DBD) containing a bipartite nuclear localization signal (NLS), which is interrupted by a 
caspase cleavage site, an automodification domain and a catalytic domain. The catalytic 
domain is the most highly conserved region of PARP 1 (25, 26), (Fig. 2). 
 
Figure 2: Structure of PARP1.  
 
 The N-terminal DBD of human PARP1 spans residues 1-373 and has a molecular 
mass of approximately 42kD. This domain contains two zinc fingers, the zinc binding motif 
and two helix-turn-helix (HTH) motifs. The two zinc fingers act as a “nick sensor” and 
recognise DNA damage. Two studies have shown that the zinc fingers are the main structures 
responsible for binding to double-strand breaks (DSBs) or single-strand breaks (SSBs) and for 
the activation of PARP1’s enzymatic activity (27, 28).  
 The automodification domain of human PARP1 extends from residues 374 to 525 
bearing a leucin zipper (LZ) motif in the N-terminal part and a BRCA1 carboxyl-terminal 
protein interaction domain (BRCT) from residues 384 to 479 in the C-terminal part. Both the 
LZs and the BRCT domain are well known to be involved in protein-protein interactions (1). 
The two zinc fingers, as well as the auto modification domain are both modified covalently by 
poly(ADP-ribose) (PAR). 
Introduction 
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 The catalytic domain of PARP1 is located in the C-terminal part of the enzyme 
between residues 526-1014. The C-terminal domain (residues 795 to 1014) of the catalytic 
domain shares several structural features with other mono(ADP-ribosyl) transferases 
including an evolutionarily conserved region, called the “PARP signature”, spanning residues 
859-908 (1). 
 
1.2.4 Enzymatic activity of PARP1 
 Poly(ADP-ribose) is a homopolymer of ADP-ribose units linked by glycosidic bonds 
and synthesized by members of the PARP family (1, 24, 25). Comparable to mono-ADP-
ribose synthesis, poly(ADP-ribose) (PAR) synthesis requires NAD+ as a substrate. The 
constitutive levels of poly(ADP-ribose) are usually very low in unstimulated cells (25, 29). 
However in response to mitogenic stimuli or genotoxic stress, the PARP activity and the 
levels of poly(ADP-ribose) may increase 10 to 500-fold, while cellular NAD+ levels are 
correspondingly reduced (22). 
 
1.2.4.1 Poly-ADP-ribosylation reaction 
 ADP-ribosylation reactions play important roles in many physiological and 
pathophysiological processes, including DNA repair, cell cycle, necrosis, apoptosis and 
transcription. PARP1’s catalytic domain supports multiple distinct reactions that lead to the 
synthesis of PAR: (i) initiation (auto-mono(ADP-ribosyl)ation), (ii) elongation, and (iii) 
branching (30). PAR exists as free (non protein bound) or protein-associated polymers, which 
are covalently or non-covalently bound to proteins (Fig. 3). The exact acceptor sites of PAR 
in proteins or in PARP1 itself are not yet known. 
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Figure 3: Poly(ADP-ribose) metabolism. Steps 1 to 3 and 4 to 7 represent the anabolic and catabolic reactions, 
respectively, in the metabolism of poly(ADP-ribose). The synthesis of poly(ADP-ribose) consists of three 
distinct PARP activities: 1) initiation of  mono-ADP- ribosylation of specific residues in the acceptor chain, 2) 
elongation of the polymer, 3) branching of the polymer. Figure adapted from (22).  
 
1.2.4.2 Structure of poly(ADP-ribose) 
 The chemical structure of poly(ADP-ribose) is well characterized. The ADP-ribose 
units in the polymer are linked by glycosidic ribose-ribose 1’-2’ bonds. The chain length of 
polymers is heterogenous and can reach 200 to 400 units in vitro and in vivo (22, 31). Long 
polymers are branched in an irregular manner. Branching occurs in vitro and in vivo with a 
frequency of approximately one branch per linear section of 20 to 50 units of ADP-ribose (31, 
32). PAR was postulated to bind to specific acceptor sites, which are unfortunately not yet 
indentified. 
 
1.2.4.3 Catabolism of poly(ADP-ribose) 
 The breakdown of free (non-protein-bound) or protein-bound linear or branched PAR 
is mediated by poly(ADP-ribose) glycohydrolase (PARG), an enzyme with both exo- and 
endoglycosidase activities that hydrolyses the glycosidic bond between ADP-ribose units, and 
thereby generates free ADP-ribose (23) (Fig. 3). 
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1.2.5 Cellular functions of PARP1 
 PARP1 was reported to play a crucial role in many physiological and 
pathophysiological processes including inter- and intracellular signalling, cell cycle 
regulation, DNA replication, DNA repair, V(D)J recombination as well as regulation of 
telomere length (1, 22). Other functions proposed for PARP1 include transcription and gene 
expression, chromatin organization, proliferation and differentiation, cellular NAD+ 
metabolism, and mitosis, as well as necrosis and apoptosis (1, 22).  
 
1.2.5.1 Role of PARP1 in transcription 
 The regulation of gene expression requires a wide array of protein factors that can 
modulate chromatin structure, act at enhancers, function as transcriptional coregulators, or 
regulate insulator functions (22). Biochemical, genomic, proteomic, and cell-based studies 
have highlighted the role of PARP1 in each of these processes and provided new insights 
about the molecular mechanisms governing PARP1-dependent regulation of gene expression 
(22). 
 Two different models were described for the interactions between PARP1 and the 
transcription machinery. The first model does not require the enzymatic activity of PARP1 
and describes the direct binding of PARP1 to transcription factors including NF-κB (1, 33, 
34) and thus influences the transcription machinery as “classical” transcriptional regulator or 
co-regulator (18, 25, 35) (Fig. 4A). The second model focuses on the remodelling of the 
chromatin structure which requires high enzymatic activity of PARP1 and 
poly(ADP)ribosylation of the histone proteins (Fig. 4B).  
 
Figure 4: Two models for the involvement of PARP1 in transcription. Model A: PARP1 at enhancer and 
promoter regions and binding to transcription factors. Model B: PARP1 modulated the chromatin structure. 
Figure adopted from (18). 
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1.2.5.2 Role of PARP1 in DNA repair 
 PARP1’s enzymatic activity correlates with DNA damage. PARP1 detects DNA nicks 
very efficiently with its two zinc fingers. The enzymatic activity of PARP1 has been shown to 
be strongly stimulated by the presence of DNA damage (18, 36). The observed affinity of 
histones to poly(ADP-ribose), especially attached to PARPs, led to the proposal of the 
‘histone shuttle’ mechanism for chromatin relaxation and recondensation in response to DNA 
damage (36-38). 
 After activation by DNA strand breaks at the site of damage, PAR synthesized by 
PARP1 and to lesser extent by PARP2 would serve as a scaffold onto which histones could be 
sequestered thus dissociating from DNA in order to render DNA accessible to the repair 
machinery, facilitating repair of damaged DNA (25, 36, 38, 39). 
 Alternatively, histones as main protein component of the chromatin, might be directly 
modified by PARPs, which would lead to their dissociation from the DNA. Histones H1 and 
H2B were shown to be poly(ADP-ribosyl)ated in vivo and to be the preferred targets of 
PARP1 in vitro (40, 41). The resulting PAR production would also signal to the cells that the 
DNA was damaged and to which extent, thereby allowing the cell to establish an appropriate 
and adaptive response according to the severity of the injury (DNA repair or cell suicide, see 
1.2.5.3). 
 
1.2.5.3 Role of PARP1 in cell death 
 PARP1 was found to influence both necrosis and apoptosis (22). A striking model 
which would explain the observed phenotype for necrosis is the link between NAD+ 
consumption by PARP1 and ATP turnover (42). The model hypothesizes that upon 
overactivation of PARP1, PARP1 plays the role of a suicide molecule by depleting the NAD+ 
and ATP pool, thereby inducing cellular dysfunction and finally necrosis (43, 44). Since 
apoptosis is ATP-dependent, PARP1 can be seen as a switch molecule that shuts down 
apoptosis and promotes necrosis. 
  Other studies however provide evidence that PARP1 can also be a positive regulator 
of apoptosis. Shuttling of apoptosis-inducing-factor (AIF) from the mitochondria to the 
nucleus is a hallmark of apoptosis (45). When cells were treated with a PARP inhibitor, 
shuttling of AIF was attenuated in a mouse model of heart failure (46). The same AIF 
shuttling was attenuated in PARP1(-/-) cells, which were subjected to oxidative stress, 
indicating that PARP1 might be involved in promoting apoptosis. It is however not yet clear 
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how the signal by PARP1 is transduced from the nucleus to the mitochondria and whether it is 
PARP1 itself or its polymers which act as signals (47). Interestingly, PARP1 is cleaved into a 
24 kDa N-terminal and a 89 kDa C-terminal fragment by caspases during apoptosis, which 
abrogates its enzymatic activity (48). However, this cleavage of PARP1 is rather a 
consequence of the apoptotic program than a required event, since mice with non-cleavable 
PARP1 showed no defect in apoptosis (49). According to the “double-edged sword” role, 
PARP1 was suggested to activate upon mild to moderate genotoxic stimuli first DNA repair. 
As a consequence DNA damage would be repaired. Upon more severe DNA damages, 
PARP1 would induce cell death. This pathway allows cells with unrepairable DNA damage to 
become eliminated in a safe way. Cleavage of PARP would avoid hyperactivation of PARP1 
by the ensuing DNA fragmentation, thus preventing cells from the pathological sequelae of 
necrosis, a less controlled mechanism posing danger for bystander cells (50). 
 
1.2.6 Mouse model 
 To study PARP1 in vivo, several PARP1 knockout (-/-) mouse models have been 
developed (51, 52). Noteworthy, only a part of the suggested functions of PARP1 based on in 
vitro results could be confirmed in vivo. PARP1 -/- mice are viable and fertile, but were 
reported to be protected against various disease models (53). A pathophysiological role of 
PARP1 has been demonstrated in a number of diseases and animal models, including 
streptotocin-induced diabetes (54-56), zymason-induced vascular failure, a non-septic model 
of multiple organ dysfunction (57), LPS-induced septic shock, and carrageenan-induced 
pleurisy (58, 59), as well as collagen-induced arthritis (CIA), a model for chronic 
inflammation (60). Cerebral ischemia is characterized by insufficient blood flow in the brain. 
It causes brain damage and death depending on the duration and severity of the condition. 
PARP1(-/-) mice were reported to be protected against cerebral ischemia (53). Interestingly, 
PARP1 enzymatic activity was strongly activated during this process. Consequently, PARP1 
inhibitors were suggested as therapeutics in the treatment of cerebrovascular diseases (61). 
The bacterial endotoxin lipopolysaccharide (LPS) activates inflammation through toll like 
receptors and causes septic shock in individuals exposed to large LPS doses. When PARP1(-/-
) mice were treated with high doses of LPS, all of them survived while most of their wild type 
littermates died (58, 62). Studies with mice lacking either PARP1 or PARP2 provide evidence 
for protection against cell death in disease models (53, 63).  
Introduction 
 
 
17 
 An attempt to create PARP1(-/-)/ PARP2(-/-) double knockout mice failed. Mice died 
during embryonic development, suggesting that PARP1 and PARP2 are involved in the same 
functions (64). 
 The proposed role of PARP1 as DNA damage sensor suggests that PARP1 works in 
concert with DNA repair proteins to protect the organism against mutation and transformation 
which would therefore be beneficial to prevent cancer. Indeed, PARP1(-/-) mice demonstrated 
increased carcinogenesis after treatment with alkylating agents (65). The double knockout 
mouse PARP1(-/-)/ p53(-/-) spontaneously develops brain tumor, further supporting the 
protective role of PARP1 in cancer (66). On the other hand, another group using a different 
strain of PARP1 (-/-)/ p53 (-/-) mice, reported attenuated tumor formation compared to wild 
type mice (67). The above mentioned contradiction could be explained by differences 
between various types of cancers and the fact that cancer is a complex, multi-step 
phenomenon on which PARP1 could have an influence via several mechanisms.  
 Along the same line, treatment of mice with PARP inhibitor suppressed tumorgenesis 
in a TPA-induced skin cancer model (68), suggesting an imported role for the enzymatic 
activity of PARP1. One possible explanation for this positive effect of PARP inhibitors on 
carcinogenesis is the reported oncogenic potential of iNOS in a p53(-/-) background, a gene 
which is regulated by PARP1 (see below). 
 
1.2.7 The role of PARP1 in LPS induced septic shock 
 The regulation of immune and inflammatory response is a complex physiological 
process that is of profound importance to both homeostasis and ultimate survival of an 
organism. Without inflammation and activation of the immune system, an organism could not 
survive the insult of injury or would rapidly succumb to invading pathogens (1). The 
inflammatory response is composed of an elaborate cascade of inflammatory mediators. Their 
regulation must be tightly coordinated to maintain appropriate and timely immune reactions 
without an over-reaction that can cause damage to the host. Yet, without mechanisms that 
shut down prolonged, inappropriate, or excessive immune response and inflammation, the 
organism would die from damage caused by these physiological responses. Therefore, both 
pro- and anti-inflammatory mechanisms must be activated and balanced for an organism to 
survive in the face of environmental stimuli that elicit an immune response (1). 
 Septic shock is the most common cause of death in intensive care units, with a high 
mortality rate, often as a result of a systemic gram-negative bacterial infection (1). It is 
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defined as an acute circulatory failure or dysfunction of a number of organ systems associated 
with severe sepsis, persisting despite adequate fluid resuscitation, causing a shock-like state 
and leading to death (69, 70). Septic shock can be mimicked in animals by intravenous 
injection of microbial products such as bacterial LPS (71). LPS activate a complex signalling 
cascade, enabling the expression of many crucial genes involved in the pathogenesis of septic 
shock, such as cytokines (e.g., TNF-α, IL-1b,) (69, 72). One of the striking features of septic 
shock is the increased production of peroxynitrite which can induce massive levels of DNA 
SSB and activation of the PARP1 “suicide-pathway”, resulting in necrotic cell death and 
endothelial dysfunction (73). It was showed that PARP inhibitors can strongly reduce tissue 
damage caused by high doses of endotoxin (73). Moreover, recent studies from different 
groups reported that PARP1(-/-) mice were extremely resistant to LPS-induced lethality (58, 
62). The production of peroxynitrite and neutrophil recruitment during endotoxic shock as 
well as local and systemic inflammation were drastically reduced in the absence of PARP1 
(58, 62).  
 
1.2.8 PARP1 as co-activator of NF-κB 
 There are striking similarities between the expression pattern of PARP1 and the 
detrimental transcriptional activity of NF-κB. In most tissues and cell types associated with 
high PARP1 expression, dysregulated NF-κB activity seems to contribute to cellular 
dysfunction and necrotic cell death during inflammatory disorders (1). The relative 
contribution of NF-κB transcriptional activity to either a “good” inflammation, manifested by 
cell survival and tissue regeneration, or a “bad” inflammation, causing dell death and tissue 
destruction, rather depends on the kinetics of activation and intrinsic metabolic differences 
between different cell types or within the same cell and on the natures as well as intensity of 
the activating stimulus (1, 74, 75).  
 Several reports showed that PARP1 is required for specific NF-κB-dependent gene 
activation and can act as a coactivator for NF-κB in vivo (35, 58, 76). PARP1 was shown to 
be required and sufficient for specific transcriptional activation of NF-κB in response to pro-
inflammatory stimuli and genotoxic stress. Neither the nuclear translocation nor the DNA-
binding ability of NF-κB were affected in PARP1(-/-) cells (1, 35, 58, 76). However, PARP1 
directly interacted through different domains with both subunits of NF-κB (p65 and p50) in 
vitro and formed a stable immunoprecipitable nuclear complex together with p50 and p65 in 
vivo, which was independent of DNA (1, 35, 76). Surprisingly, neither the enzymatic activity 
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of PARP1 nor its DNA-binding activity was required for full activation of NF-κB in response 
to various stimuli in vivo (76, 77). The strongest indication for a direct role of PARP1 in NF-
κB-dependent transcription is the impaired expression of NF-κB-dependent pro inflammatory 
mediators in PARP1(-/-) mice (53). The fact that PARP1(-/-) mice do not show the same 
phenotype compared to RelA/p65(-/-) animals, indicates that only subsets of NF-κB-
dependent genes are dependent on PARP1, such as iNOS or TNF-α. RelA/p65 was described 
to interact directly with the basal transcription machinery as well as with distinct sets of 
transcriptional co-factors and co-activators (1, 78). Thus, in certain instances, the requirement 
for PARP1 is possibly bypassed through other specific co-activators and co-factors, most 
probably in a cell type- and stimuli-dependent manner (1). 
 
1.3 Cell cycle 
1.3.1 Introduction 
 The cell cycle, or cell division cycle, is the series of events that take place in a 
eukaryotic cell leading to its duplication (79, 80), (Fig. 5). These events can be divided in two 
brief periods: Interphase and mitotic phase. 
        
Figure 5: Cell cycle phases. G1 = growth phase 1, S = synthesis of DNA, G2 = growth phase 2, M = mitosis 
   (80). 
 
 During the mitotic phase the cell divides into two daughter cells. During the rest of the 
cycle (the Interphase) the cell is constantly synthesizing RNA, producing protein, growing in 
size and duplicating its DNA (79). Interphase generally lasts at least 12 to 24 hours in 
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mammalian tissue. Mitosis is much shorter than interphase, lasting only one to three hours 
(79). 
1.3.2 Cell cycle phases 
 Throughout interphase, the cell is engaged in growth and metabolic activities. 
Interphase can be further broken down into 3 discrete phases named G1, S and G2. During G1 
or first growth phase, cells grow and prepare for the replication of their DNA. In S phase, 
synthesis of DNA takes place by producing two DNA replicates of each chromosome. During 
G2 phase, the cell continues to prepare for mitosis and cell division (79). 
 Mitosis or the mitotic phase has four stages: Prophase, metaphase, anaphase and 
telophase (79). During prophase the chromosomes become visible and condense, shorter and 
thicker. Each identical copy of a single chromosome is called a sister chromatid. The nuclear 
envelope breaks down and spindle fibers form as microtubules grow out of the centrioles that 
move to opposite poles of the cell. During metaphase, the chromosomes line up along the 
equator of the cell. The spindle is now fully formed and the microtubules attach to each sister 
chromatid. Anaphase begins when the sister chromatids of each chromosome begin to 
separate. The centromere that holds sister chromatids together divides and the chromosomes 
move away from each other along the spindle fiber. In telophase, the two groups of 
chromosomes reach the opposite ends of the cell. As a result of the previous nuclear envelop 
break down, two new membranes starts to form around each group, the chromosomes uncoil 
and the spindle disappears. The division of the cytoplasm and organelles is called cytokinesis. 
The result of mitosis and cytokinesis is the formation of two genetically identical daughter 
cells (79).  
 
1.3.3 Control of the cell cycle 
 Regulation of the cell cycle involves crucial steps, including detection and repair of 
genetic damage. The progression through the cell cycle is controlled by proteins. Two key 
classes of regulatory molecules, cyclines and cyclin-dependent kinases (CDKs) are 
responsible for this regulation (81). The protein levels of cyclines (cyclin D (G1 phase), 
cyclines E and A (S phase), and cyclines B and A (mitotic phase)) rise and fall with the stages 
of the cell cycle, while the protein levels of CDKs (CDK4 (G1), CDK2 (S phase), and CDK1 
(mitotic phase)) remain fairly stable (Fig. 6).  
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  Figure 6: Cell cycle phases and corresponding Cdk-Cyclin levels (79). 
 
 Each CDK must bind to its appropriate cyclin (whose levels fluctuate) in order to be 
activated. The availability and formation of the cyclin-CDK complex thus allows progression 
through the cell cycle (81). 
 
1.3.4 Cell cycle synchronization 
 Cell synchronization is required to study the behaviour of the cells in different cell 
cycle stages. Synchronization is achieved by two different techniques – physical cell 
separation and chemical blockade (82). Physical cell separation is performed based on cell 
density, cell size, affinity of antibodies and on fluorescent emission by labelled cells. Cell 
synchronization by chemical blockade can be caused by nutritional deprivation or by 
chemicals interfering with DNA synthesis or by inhibiting microtubules dynamic. DNA 
synthesis inhibitors are used to arrest the replicating cells in S phase. Inhibitors commonly 
used are those that inhibit the synthesis of deoxyribonucleotide triphosphates, such as 
thymidine at high concentrations or more drastically hydroxyurea. Alternativly the direct 
DNA polymerase inhibitor aphidicolin can be used.  
 To arrest cells at G2/M phase the antimitotic agent nocodazol is often used. It disrupts 
microtubule formation by binding to β-tubulin and prevents formation of one of the two 
interchain disulfides linkages. Nocodazol disrupts subsequently the mitotic spindle function, 
and induces fragmentation of the golgi complex. As a result, cells are arrested in G2/M phase 
(83). Usually, cells that are not in the preferred phase at the time of treatment with inhibitors, 
will be arrested when they pass the phase the next time (82). Prolonged treatment with 
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thymidine, hydroxyurea and aphidicolin can be toxic to cells, and thus does not always block 
cells securely at the G1/S boundary (82). 
 One way to assess the phase of cells, is by measuring its DNA content, which doubles 
during S phase. This approach is greatly facilitated by the use of a DNA-binding fluorescent 
dye (PI) and the fluorescence activated cell sorting machine (FACS), which allows the rapid 
analysis of a large number of cells (84).  
 
1.4   Connection between cell cycle and NF-κB or PARP1 
1.4.1 Cell cycle and NF-κB-transcriptional activation 
 The transcriptional activity of a cell has to be tightly controlled during the cell cycle, 
since transcription and replication are both using DNA as template (79). During G1 and G2 
phase only transcription takes place. The challenges for the transcription during S phase are 
two-folded; first the DNA synthesis induces the relaxation of the chromatin structure and thus 
allows transcription factors to bind more easily to the DNA. Second, ongoing replication 
might interfere with transcription at the same DNA strand (79). During mitosis the cell faces 
various additionally challenges, since chromatin condensation and numerous mitotic activities 
might interfere in different ways with the binding between the transcription factors and the 
chromatin (79). 
 Some investigation how NF-κB transcriptional activity is regulated during cell cycle 
has been recently reported (85). Perkins and co-workers showed that the processing of the 
p100 NF-κB subunit to p52 is inhibited in U2OS cells and MEFs during S phase. They also 
reported that RelA/p65 phosphorylation changes during cell cycle. RelA is predominantely 
phophorylated at S468 in G1 phase, while S536 phosphorylation is low in G1 phase but 
becomes apparent in S phase and is peaking in G2 phase. This differential RelA/p65 
phosphorylation in the G1 and G2 phases is IKK-dependent (85). These observed 
mechanisms go along with parallel control of important target genes during cell cycle, what 
results in activated cyclin D1, c-Myc and Skp2 expression during G1 phase and reduced 
cyclin D1, c-Myc and Skp2 expression during S and G2 phase (85). Taken together, these 
data reveal a previously unknown and dynamic regulation of NF-κB activity across the cell 
cycle.  Although many of these activities depend at some level on IKKα or β, observations 
suggest that other signalling pathways must coordinate these events and integrate with the 
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NF-κB signalling pathway in a cell cycle-dependent manner. It was also reported that active 
Akt and Chk1 fluctuate during cell cycle and regulate IKK/NF-κB activity (85).  
1.4.2 Cell cycle and PARP1 
 Poly(ADP-ribosyl)ation plays an important role in a large variety of physiological 
processes also including cell cycle, but its role in cell cycle progression is not yet defined 
(50). Recently a functional interaction between mitogen-activated protein kinase (MAPK) 
signalling and PARP1 activation was reported (50). It has been well established that the 
MAPK pathway plays an important role in the activation of the cell cycle machinery in 
mitogen stimulated cells, thereby suggesting a possible role of PARP activity in linking 
growth factor signalling with cell cycle entry (50). Whether the enzymatic activity of PARP1 
is dependent for the propagation through the cell cycle phases has not yet been investigated. 
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1.5 Aim of this thesis 
 Despite the notable physiological relevance of NF-κB, little details are known about 
the nuclear mechanism enabling NF-κB-dependent gene expression during the different 
phases of the cell cycle. 
 The aim of this thesis was to shed light on the physiological role of PARP1 as 
transcriptional co-factor for NF-κB-dependent gene expression during the cell cycle. A better 
understanding of the NF-κB physiology and of factors influencing the expression of NF-κB 
target genes is of great importance, since NF-κB has been implicated in different cellular 
processes and in a broad range of diseases, such as LPS induced septic shock. 
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2 Results 
2.1  LPS induces NF-κB target genes in RAW 267.4 macrophages 
 In order to investigate the functional relevance of PARP1 in transcription, we 
stimulated RAW 267.4 macrophages with LPS (10 µg/ml for 1 hour). Total RNA was isolated 
and several genes were analysed by qRT-PCR. Chosen genes had already been described to 
be NF-κB target gene or were known to be important for the regulation of inflammation. 
Finally some genes were selected based on own previous observations (unpublished data), 
(Tab. 1).  
           
Table 1: Table of all genes we investigated with our cell synchronization system. Bad = no specific product 
formed, good = single specific product was formed before cycle 35, 0 = no difference between stimulated versus 
unstimulated, n.d. = not detectable, due to non-functional primer (e.g. Primer dimmer formation or low 
detectable mRNA content. 
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 While for some genes the RNA could not be detected by qRT-PCR, most probably 
due to inappropriate primers, other genes such as IL-1b, IL-12, IP-10, Csf2, Mpa2l or Lif 
could be quantified and showed a strong induction by LPS (Tab. 1). Gene expression was 
normalized to RPS12 or GAPDH, two genes that were earlier described not to be affected by 
LPS or the cell cycle. A third group of target genes was not stimulated by LPS (e.g. IL-15, 
Hif1an). We therefore decided to further analyse the following six LPS induced genes, in a 
more detailed manner: IL-1b, Csf2, IL-12, IP-10, Mpa2l and Lif.  
 
2.2 Knockdown of PARP1 by a short hairpin RNA construct 
results in a stable reduction of PARP1 protein levels in RAW 
267.4 macrophages 
 In order to investigate the possible involvement of PARP1 in NF-κB-dependent gene 
expression, a PARP1 knockout or knockdown cell system and the corresponding control cells 
are required. Therefore, PARP1 was knocked down in RAW 267.4 macrophages by a short 
hairpin (sh) RNA approach. Parental RAW 267.4 macrophages were transduced with a 
retrovirus constitutively expressing either a shPARP1 or a shMock (scrambled sequence) 
RNA construct. Upon transduction, cells were selected for successful integration. The 
efficiency of the shPARP1 construct to knockdown PARP1 was tested by Western blot 
analysis using an anti-PARP1 antibody. Western blot analysis revealed a distinct signal for 
cells expressing shMock and no signal of PARP1 for cells expressing the shPARP1 construct 
(Fig 7A), indicating that the knockdown was very efficient. 
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Figure 7: shPARP1 knockdown was controlled by Western blot (A) and qRT-PCR (B) for PARP1. For the qRT-
PCR both unstimulated and 1h stimulated (LPS, 10µg/ml) shMock or shPARP1 cells were examinated.  
 
 Additionally, the absolute PARP1 gene expression levels in unstimulated or LPS 
stimulated shMock or shPARP1 cells were analysed by qRT-PCR. qRT-PCR results revealed 
that the PARP1 mRNA levels were drastically decreased in shPARP1 cells. The residual 
PARP1 mRNA levels were less than 6% or 4% for unstimulated or LPS stimulated cells 
respectively (Fig. 7B). LPS itself did not alter PARP1 expression. 
 These data confirmed that the retroviral shRNA successfully reduced PARP1 protein 
levels. Additionally, the shMock cells provide an appropriate control for the tested system.  
2.3 PARP1 functions in unsynchronized cells dependent on the 
gene as transcriptional co-activator or as co-repressor 
 In order to define whether the six chosen genes were PARP1-dependent, shPARP1 
and shMock cells were treated for 1 hour with LPS (10ug/ml). Total RNA was subsequently 
isolated and quantified by qRT-PCR (Fig. 8). 
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Figure 8: Unsynchronized shMock and shPARP1 RAW 267.4 macrophages were stimulated with LPS as 
indicated. RNA was isolated to analyse gene expression levels by qRT-PCR. The left panel shows the absolute 
gene expression levels from each gene (shMock unstimulated level set as 1) and the right panel shows the fold 
induction (unstimulated shMock and shPARP1 set as 1). Standard error bars are calculated from 2 or 3 biological 
replicates and additional 2 or 3 techniques replicates. 
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 The quantification of the absolute mRNA gene expression levels of stimulated and 
unstimulated shMock or shPARP1 cells are shown in Fig. 8 left panel. shMock unstimulated 
value was arbitrary set to 1. In the same Figure (right panel), the fold induction is shown as 
the result of the stimulation difference between unstimulated and stimulated cells. Here both 
values from unstimulated shMock and shPARP1 cells were set to 1. Interestingly, while the 
expression levels of IL-1b, IL12, Csf2 and Mpa2l were reduced in shMock cells, suggesting 
that PARP1 functions as co-repressor, the expression pattern for IP-10 was exactly opposite 
(higher for shMock cells) suggesting that PARP1 acts for this gene as co-activator. Lif gene 
expression was not affected by the reduction of PARP1. 
 These data provide evidence that PARP1 acts dependent on the analysed gene either 
as transcriptional co-repressor or co-activator. 
 
2.4  Induction of cell cycle arrests in shMock and shPARP1 RAW 
267.4 macrophages 
 In order to investigate whether the cell cycle would effect NF-κB-dependent gene 
expression through the involvement of PARP1 as transcriptional co-factor, we synchronized 
the transduced cells by different chemical treatments. To arrest cells in the different cell cycle 
phases we treated them with either Thymidine, Aphidicolin or Nocodazol. Thymidine 
treatment causes a cell cycle block at the G1/S boundary (82). Upon treatment with 
Aphidicolin the cells should peak in early S phase, since Aphidicolin inhibits DNA 
polymerase (82). Nocodazol on the other hand inhibits microtubule dynamics, disruption of 
mitotic spindle function, and fragmentation of the golgi complex which results in a cell cycle 
arrest in G2/M phase (83). Cells were synchronized during 14 to 15 hours with the 
corresponding compound, subsequently treated with LPS for one hour to induce NF-κB. After 
this treatment of synchronization, stimulated or unstimulated cells were stained with 
Propidium Iodid (PI) to be able to analyse their cell cycle distribution by FACS.  
 The FACS analysis represents the fluorescence intensity, which correlates with the 
contents of DNA and the number of cells with the corresonding amount of DNA 
(fluorescence). Unsynchronized cells characteristically are distributed in two peaks. The first 
peak represents cells in G1 with a diploide genome (2n, 2c). The second peak represents cells 
with a replicated genome (2n, 4c) and correlates with cells in G2/M phase. Cells in between 
these peaks are in S phase, replicating the DNA content from 2c to 4c (Fig 9. top left panel).  
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Figure 9: Unsynchronized cells were synchronized with the corresponding compound (Thymidine: 0.6 mg/ml, 
15h; Aphidicolin: 5µg/ml, 14h; Nocodazol: 0.4µg/ml, 15h). Cells were PI stained and analysed by FACS, where 
always 103 cells were measured. 
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 Treatment of cells with Thymidine arrested them to 73% in G1 (Fig. 9 and Tab. 2).  
After 3 hours release, the peak (representing 69% of the cells) moved to the right into S 
phase. Aphidicolin treatment also induced a nice G1/S peak. Noteworthy, this peak was very 
high on the y scale (up to 2600) and cells were synchronized very well (82%). After 
Nocodazol treatment the cells peaked in G2/M (83%). 
 Together, treatment of the cells with different compounds nicely arrested them in the 
corresponding phase of the cell cycle. Overall the treatment did not induce strong apoptosis, 
since not more than 8% of the cells died according to the FACS analysis. Additional treatment 
with LPS for 1 hour did not affect the cell cycle arrest (data not shown). Interestingly, lack of 
PARP1 did not affect cell cycle distribution (Fig. 9 right panel). 
Table 2: During FACS analysis the percentage of cells in each cell cycle phase was calculated by the machine. 
  Numbers are from a representative experiment. 
 
 From these data we concluded: i) treatments synchronized cells at the expected cell 
cycle phase, indicating that the cellular cell cycle arrest mechanisms were intact in the 
analysed cells, ii) the established protocols are not too stressfully for the cells, since the 
amount of dead cells never exceeded 8%, iii) compounds synchronized the cells in a PARP1 
independent manner (shMock vs. shPARP1) and independent of the stimulation by LPS. 
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2.5 Cell cycle synchronization induces poly(ADP-ribose) polymer 
formation 
 To test, whether the treatment with different cell synchronization compounds would 
affect the physiological function of PARP1, whole cell extracts were generated from the 
shMock RAW macrophages after each synchronization treatment. Extracts were subsequently 
analysed by Western Blot analysis using antibody against PARP1 or PAR. While PARP1 
protein levels were not changed upon cell cycle synchronization, some treatments induced 
detectable PAR formation (Fig. 10 A and B). 
Figure 10: Whole cell extracts from shMock cells were isolated after each cell cycle block, and analysed by 
Western Blot. A: Western Blot using an anti PARP1 antibody. B: Western Blot using an anti PAR antibody. 
 
 Although Western Blot analysis does not allow a quantitative statement, it was 
obvious that the different treatment would induce PAR polymers of different quality and 
quantity. Aphidicolin and Thymidine induced rather short polymers and Nocodazol very long 
one. Release of cells from Thymidine block resulted in a much weaker PAR signal, 
suggesting that formed PAR was subsequently degraded again. Interestingly the PAR 
induction did not induce strong apoptosis (see above) under the tested conditions.  
 Together these results suggested, that synchronization of cells with chemical 
compounds is inducing PARP1’s enzymatic activity and might influence the function of 
PARP1 and consequently also its involvement in transcription. 
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2.6 Cell cycle arrest induces NF-κB-dependent gene expression 
only slightly 
 To further analyse the influence of the cell cycle on NF-κB-dependent gene 
expression, we tested whether the different cell cycle arrests would induce basal levels of NF-
κB-dependent gene expression and whether the cells would still be stimulatable by LPS. In 
order to answer these questions we analysed the IP-10 mRNA levels of unsynchronized 
unstimulated, synchronized unstimulated and synchronized stimulated shMock RAW 267.4 
macrophages (Fig. 11). 
Figure 11: IP-10 gene expression of cells differentially synchronized and subsequently stimulated by LPS (A = 
Aphidicolin, B = Nocodazol, C = Thymidine or D = Thymidine and release). 
 
 While the basal IP-10 mRNA levels were only slightly elevated after Aphidicolin, 
Thymidine, Thymidine and release or after Nocodazol treatment (10 to 40 fold), additional 
stimulation by LPS for 1 hour resulted in combination with Aphidiclin treatment in a very 
strong 450 fold IP-10 induction. An additional stimulation of 80 to 250 fold was observed for 
cells treated with Nocodazol, Thymidine or Thymidine and release, respectively. The analysis 
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of other genes (such as IL-1b, IL-12, Csf2, Lif) confirmed the same pattern of gene 
expression as indicated in Fig. 10 (data not shown). Together, these data provide strong 
evidence, that the different cell cycle arrests induced NF-κB only slightly and that a 
subsequent LPS stimulation was able to induce a significant upregulation of the tested NF-κB 
target genes. 
 
2.7 PARP1 is a transcriptional co-repressor for IL-1b, IL-12 and 
Csf2 gene expression throughout the cell cycle 
 The established cell cycle synchronization protocol allowed us to further investigate 
the transcriptional role of PARP1 during cell cycle. shMock and shPARP1 cells were 
individually synchronized and additionally treated with LPS (where indicated). After LPS 
treatment, total mRNA was isolated and analysed by qRT-PCR. 
 Gene expression analysis of IL-1b, IL-12 and Csf2 revealed that in unsynchronized 
cells PARP1 functions as co-repressor, since knockdown of PARP1 resulted in an increased 
gene expression and fold induction (Fig. 12, 13, 14). Synchronization with Thymidine, 
Thymidine and release or Nocodazol treatment did not change inducibility pattern of the 
tested genes (compared to unsynchronized cells), suggesting that PARP1 function also in 
G1/S and G2 as co-repressor (Fig. 12, 13, 14).  
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Figure 12: Absolute gene expression levels and fold induction values for IL-1b were analysed by qRT-PCR after 
the different synchronisation treatments. Standard error bars are calculated from 2 or 3 biological replicates and 
additional 2 or 3 techniques replicates. 
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Figure 13: Absolute gene expression levels and fold induction values for Csf2 were analysed by qRT-PCR after 
the different synchronisation treatments. Standard error bars are calculated from 2 or 3 biological replicates and 
additional 2 or 3 techniques replicates. 
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Figure 14: Absolute gene expression levels and fold induction values for IL-12 were analysed by qRT-PCR after 
the different synchronisation treatments. Standard error bars are calculated from 2 or 3 biological replicates and 
additional 2 or 3 techniques replicates. 
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 Comparison of the gene expression levels from unsynchronized and synchronized 
stimulated shMock cells revealed that cell cycle arrest affected gene induction, however in 
different ways. While for IL-1b the stimulation was very high (1000 fold induction in 
unsynchronized cells), synchronization of cells reduced the values strongly (down to 40 and 
60 fold). Remarkably, the inducibility of Csf2 went up slightly from 50 to 60 fold upon 
Thymidine and release treatment, suggesting that cells under these conditions are better 
stimulatable compared to unsynchronized cells. For IL-12 cells treated with Thymidine and 
Thymidine and release showed a quiet high fold induction (between 330 and 350 fold), only 
the Nocodazol treatment reduced fold induction.  
  Together, these results suggest that PARP1 is a transcriptional co-repressor for NF-
κB-dependent gene expression of IL-1b, IL-12 and Csf2. 
 
2.8 PARP1 is a transcriptional co-activator in unsynchronized 
cells, but a co-repressor during G1/S phase for IP-10 gene 
expression 
 Analysis of IP-10 gene expression revealed that in unsynchronized cells PARP1 
functions in contrast to the other so far analysed cells as co-activator, since knockdown of 
PARP1 in the shPARP1 cells resulted in a reduced gene induction (Fig. 15). 
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Figure 15: IP-10 gene expression levels and fold induction values were analysed by qRT-PCR upon different 
synchronisation treatments and LPS stimulation. Standard error bars are calculated from 2 or 3 biological 
replicates and additional 2 or 3 techniques replicates. 
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 Surprisingly, synchronization with Thymidine reversed the stimulation pattern, suggesting 
that PARP1 would function as co-repressor under these conditions. Upon Thymidine 
treatment and release, no difference in IP-10 gene expression levels and fold induction could 
be detected. Nocodazol on the other hand restored the expression pattern to the one observed 
in unsynchronized cells. Interestingly, the overall IP-10 gene expression levels were 
significant reduced after having arrested the cells in the different phases (480 fold for 
unsynchronized cells, versus approximately 100 fold upon Thymidine treatment or 40 fold 
after Nocodazol treatment). The reduced induction was not due to increased basal levels. 
 Together, these results suggest that PARP1 does regulate IP-10 gene expression in a 
cell cycle-dependent manner. While in unsynchronized cells and cells arrested at G2/M phase, 
PARP1 acts as co-activator, PARP1 would act in early G1/S phase as co-repressor which 
would again change 3 hours later in middle of S phase, where gene expression levels seem not 
to be dependent on PARP1. 
 
2.9 PARP1 is a transcriptional co-repressor in unsynchronized 
cells, but a co-activator during S phase for Mpa2l gene 
expression 
 ShMock and shPARP1 cells were also analysed for LPS induced Mpa2l gene 
expression. This analysis revealed that in unsynchronized cells PARP1 would function 
comparable to IL-1b, Csf2 and IL-12 as co-repressor, since knockdown of PARP1 resulted in 
an increased gene expression and fold induction (Fig. 16). However, synchronization with 
Thymidine, Aphidicolin and Nocodazol treatment reduced PARP1 dependency since after 
these treatments no gene expression differences could be observed (Fig. 16). Surprisingly, 
after Thymidine and release treatment, PARP1 would function as transcriptional co-activator, 
since the gene expression values were lower when shPARP1 cells were used.  
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Figure 16: Absolute gene expression levels and fold induction values for Mpa2l were analysed by qRT-PCR 
after the different synchronisation treatments. Standard error bars are calculated from 2 or 3 biological replicates 
and additional 2 or 3 techniques replicates. 
Results 
 
 
42 
 Togheter, these results suggest that PARP1 does regulate Mpa2l gene expression in a 
cell cycle-dependent manner. While in unsynchronized cells PARP1 acts as co-repressor, it 
acts as co-activator in middle S phase. During G1/S and G2/M phase, NF-κB-dependent gene 
expression is PARP1 independent. 
 
2.10 Lif gene expression is independent of PARP1 in 
 unsynchronized cells, but during G1/S phase PARP1 acts as 
 co-activator 
 Gene expression analysis revealed earlier, that Lif gene expression was independent of 
PARP1 in unsynchronized cells. Repeating the analysis for Lif gene expression with 
synchronized cells revealed, that after the Thymidine and Nocodazol treatment the gene 
expression levels and fold induction values are explicitly increased for shMock cells 
compared to shPARP1 cells (Fig. 17), suggesting that PARP1 acts as co-activator. 
Surprisingly synchronization with Thymidine and release reversed the stimulation pattern, 
suggesting that PARP1 functions under these conditions as co-repressor. 
 These data suggest that PARP1 would function during the cell cycle as co-activator as 
well as co-repressor and that the result obtained with unsynchronized cells represents the sum 
of all phases. 
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Figure 17: Absolute gene expression levels and fold induction values for Lif were analysed by qRT-PCR after 
the different synchronisation treatments. Standard error bars are calculated from 2 or 3 biological replicates and 
additional 2 or 3 techniques replicates. 
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3 Discussion 
 The aim of this thesis was to investigate the possible involvement of PARP1 in NF-
κB-induced gene expression during cell cycle. LPS activated several NF-κB target genes in 
RAW 267.4 macrophages, identifying these cells as valuable tool. Retroviral transduction of 
the RAW 267.4 macrophages allowed the integration and expression of either a shRNA 
construct directed against PARP1 or a scrambled construct (as control). PARP1 protein levels 
were subsequently significantly reduced using the short hairpin (sh) RNA approach. Analyses 
of NF-κB target gene expression after LPS stimulation revealed that dependent on the 
analysed gene, PARP1 acts either as co-repressor or as co-activator. Treatment of these cells 
with different chemical compounds, such as Aphidicolin, Thymidine or Nocodazol 
synchronised cells at different phases of the cell cycle, while only a small amount of the cells 
(less than 8%) died due to the treatment. Furthermore, cell cycle arrest induced NF-κB-
dependent gene expression only slightly, while subsequent LPS stimulation was able to 
substantially induce an additional upregulation of several tested NF-κB target genes. 
Interestingly, knockdown of PARP1 did not affect synchronisation. Further analysis of 
PARP1, however, revealed that cell cycle synchronization induced PAR formation, although 
PARP1 protein levels were not changed. Cell cycle-dependent analyses of several LPS-
induced NF-κB-target genes in unsynchronized cells revealed that PARP1 again would have a 
dual function. PARP1 acted as co-repressor for Csf2, IL-1b and IL-12 which was not 
influenced by cell cycle synchronization. For two tested genes, i.e. IP10 or Mpa2l, PARP1 
acted as co-activator (IP-10) or as co-repressor (Mpa2l) in unsynchronized cells, which 
however changed upon the corresponding synchronization of the cells to the opposite type of 
function. In Thymidine (early S phase) and Aphidicolin (early S phase) treated cells, PARP1 
acted as co-repressor for IP10 and in Thymidine and release (early S phase) treated cells, 
PARP1 acted as co-activator for Mpa2l. In unsynchronized cells, gene expression for Lif is 
PARP1 independent, while after Thymidine (early S phase) and Nodocazol (G2/M) 
treatement, PARP1 acted as co-activator.  
 While genes such as IL-1b, IL-12, and IP-10 were reproducibly induced to a high 
degree, no induction was observed for other genes such as IL-15, a previously described NF-
κB target gene (86). Given that LPS induced other genes, and that the primer per se were 
functioning (judged by the production of only one single PCR product, confirmed by the 
melting curve and by agarose gel electrophoresis), we concluded that the IL-15 gene was after 
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LPS treatment for 1 hour not or only very weakly induced in the tested Raw macrophages. 
The reason remains to be elucidated. 
 The observed contribution of PARP1 in NF-κB-dependent gene expression never 
reached 100% (i.e. complete loss of gene expression) which could be explained by the fact, 
that although PARP1 levels could not anymore be detected by western blot analysis in the 
shPARP1 treated cells, there was a rest amount of PARP1 molecules which would interfere 
with our analysis. Furthermore, we cannot exclude that other PARP family members might 
functionally complement the loss of PARP1 in the shPARP1 macrophages. 
 Strikingly, PARP1 functions for some genes in unsynchronized cells as transcriptional 
co-activator, and as co-repressor for others. The association of PARP1 with the chromatin 
could possibly explain the two opposing functions. Depending on the nucleosomal 
environment around the transcription start site (e.g. nucleosomal positioning or modification 
of the histone tails), PARP1 might either increase the accessibility for NF-κB to its response 
element and thus enhance gene expression or, alternatively, reduce NF-κB DNA binding and 
subsequently the extent of gene expression. Especially the repressor function of PARP1 
would guarantee that pro-inflammatory cytokines are not strongly expressed, which would be 
detrimental for the organism. An alternative explanation would be, that PARP1 would act as 
promotor-specific exchange factor which would recruit to the transcriptional start site either 
co-activator or co-repressor complexes, as it was suggested for the activation of specific 
neurogenic gene programs (87). PARP1 might regulate NF-κB-dependent gene expression 
dependent on the exposure time of a cell to LPS, which could be part of a negative feedback 
loop and help to attenuate harmful gene expression. For some “early” genes such as Csf2 and 
IL-12, the putative negative feedback might already be activated after one hour LPS 
stimulation, while for “late” genes such as IP-10 it might take longer to activate the postulated 
negative feedback. This hypothesis is further supported by the fact, that after 4h LPS 
stimulation also for IP-10 a co-repressor activity for PARP1 was observed (data not shown). 
The same switch was also observed after different times of LPS stimulation. Whether this 
feedback mechanism holds true, has to be tested for more genes and also including different 
other stimuli. 
 Gene expression analyses of unsynchronized cells are always the sum of the 
expression profiles of cells in the different phases. It can be easily foreseen, that gene 
expression during S phase is additionally influenced by the replication machinery of the cell 
and possibly by the modification of the chromatin, which is required to replicate the DNA. To 
elucidate mechanistic regulation by proteins on transcription, it is thus important to also 
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analyze gene expression in distinct phases of the cell cycle. To simplify our analysis, we 
decided to analyze RNA from cell cycle synchronized samples only 1 hour after LPS 
stimulation. Chemical compounds arrested the cells to the similar extent in the desired phase, 
independent PARP1 being present or knocked down, suggesting that PARP1 is not required 
for the arrest of cells at defined phases. On the other hand cell cycle arrest induced NF-κB-
dependent gene expression only slightly and still allowed further stimulation by LPS.  
 The differential observed contribution of PARP1 in gene expression (co-activator or 
co-repressor) was not only observed in a gene-type and induction time specific manner, but 
was also observed for a defined gene such as IP10, Mpa2l or Lif in a cell cycle-dependent 
manner (for a given gene at 1 hour LPS stimulation). These results suggest that the cell cycle 
does influence PARP1 and consequently also PARP1-dependent gene expression. Since the 
synchronization of cells also induced the enzymatic activity of PARP1 (but not its protein 
levels), the observed changes might be dependent on the treatment. The enzymatic activity of 
PARP1 was earlier described to be important for the remodeling of the chromatin structure 
(18). On the other hand, our laboratory provided earlier evidences, that the enzymatic activity 
of PARP1 was not required for transcriptional activation of transiently transfected reporter 
genes (22). The fact that PARP1’s function was not changed for all genes to the same extend 
and in the same cell cycle phase (e.g. always changing in Thymidine treated cell), suggests 
that there might exist an additional so far unrecognized level of PARP1’s involvement in 
transcriptional regulation. Furthermore, experiments with cells synchronized by other growth 
arrest, revealed that PARP1 forms PAR polymers upon entering the S phase (personal 
communication, Suheda Erener) suggesting that the observed enzymatic activity of PARP1 
might in part still be physiological relevant. This theory would be supported by the fact that 
some cell cycle activities are influencing PARP1 (85). One mechanism to activate PARP1, 
also in a DNA-damage independent manner, would be by post-translational modification. 
PARP1 was recently described to be phosphorylated by different kinases (88). 
 Together our results provide strong evidences for the involvement of PARP1 in NF-
κB-dependent gene expression during the cell cycle, although the mechanisms regulating 
these processes have to be further elucidated. Whether these results are also valid and 
observed when cells are stimulated with other NF-κB inducing stimuli and found in other cell 
types has also to be further analyzed. 
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Outlook and medical relevance 
 It is proposed that the finding, that PARP1 has a cofactor function for NF-κB, might 
help to design new therapeutic strategies for treatment of inflammatory disorders, based on 
the combined pharmalogical inhibition of NF-κB and PARP1 interaction (58). A variety of 
widely used anti-inflammatory agents inhibit the NF-κB pathway, resulting in a decrease in 
NF-κB-dependent transcription (89). However, blocking the NF-κB pathway for prolonged 
periods is not feasible, since NF-κB plays an important role in the maintenance of the host 
defense responses. Moreover, since PARP inhibitors are not only able to inhibit the enzymatic 
activity of PARP1 but also other PARPs, complete long-term inhibition of the enzymatic 
activity of PARP1 might lead to severe side effects. Therefore, the NF-κB/PARP1 interface 
might be an obvious target for the development of new types of drugs disrupting specific 
protein-protein interactions during the whole cell cycle. Taken together, future investigations 
of the various roles of PARP1 in transcription and signaling under pathophysiological 
conditions in vivo, will certainly represent an intense exciting field of research (1). 
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4 Material and Methods 
4.1 Material 
4.1.1 Cell lines 
 All experiments were performed with RAW 264.7 macrophages. These are mouse 
monocytes/macrophages originally isolated from a mouse tumor induced by a Abselon 
Leukaemia virus. PARP1 knockdown was achieved by retroviral transduction of cells with 
(bistronic self-inactivating) lentiviral vector expressing sh(short hairpin)RNAs directed 
against PARP1 mRNA, which resulted in a stable reduction of PARP1 protein levels. Control 
cells were transduced with a retroviral shMock RNA construct.  
 
 Adherent Raw 267.4 macrophages were grown in RPMI medium in the presence of 
10% fetal calf serum (FCS) and penicillin (50U/ml)/streptomycin (50µg/ml). Cells doubled 
approximately every 24 hours and were split 1:3 when they reached 90% confluence. 
 
4.1.2 Solutions 
 
Solutions for cell culture 
 
Medium:   GIBCO RPMI 1640 Medium (1X), liquid,  
     with L-Glutamine (Invitrogen)  
     Supplemented with 10% fetal calf serum (FCS)  
     (Invitrogen), 50U/ml Penicilllin (Invitrogen) and  
     50µg/ml streptomycin (Invitrogen) 
 
PBS (10x)   1.37M NaCl 
     100mM Na2HPO4 • H2O 
     30mM KH2PO4 
     ad 1L H2O 
     adjust PH 7.4 (with HCl) 
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Solutions for the generation of whole cell extracts 
 
Lysis Buffer:   50mM Tris/HCl pH 7.5 
     400mM NaCl 
     25mM NaF 
     1% (v/v) Triton X-100 
 
 
Solution to define protein concentrations: 
 
5x Bradford Solution  BIO-RAD Protein Assay (Bio-Rad Laboratories   
    GmBH) 
 
Standard proteins  bovine serum albumin, homemade in the own   
    lab (concentrations: 0.2, 0.36, 0.54 and 0.72 mg/ml) 
 
 
Solution for SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Running buffer     1.5M Tris pH 8 
     0.4% (w/v) SDS 
 
Separation Gel (10%)  4ml ddH2O      
     2ml Solution B 
     2ml 40% acrylamide solution 
     0.08ml 10% APS 
     0.008 ml TEMED 
 
Solution B    1.5 M Tris /HCl pH 8.8 
     0.4% Na-dodecylsulfate (SDS) 
     ad 200ml ddH2O 
 
Stacking Gel (4.8%)  3.15 ml ddH2O 
     1.25 ml Solution C 
     0.6 ml 40% acrylamide solution 
     add immediately before use: 
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     0.05 ml 10% APS 
     0.005 ml TEMED 
 
Solution C    0.5 M Tris/HCl pH 6.8 
     0.4% Na-dodecylsulfate (SDS) 
     tipfull Bromphenol blue 
     ad 200ml ddH2O 
 
40% Acrylamide Solution Acrylamid-Bis (solution (37.5:1), 40% (w/v)), SERVA  
    biosystems GmBH 
 
10x protein loading buffer 600mmol/l Tris-HCL pH 6.8 
     20% Na-dodecylsulfate 
     20% Glycerol 
     0.05% Bromphenol blue 
     20% Mercaptoethanol 
     25mmol/l DTT 
 
 
Solutions for Western Blot analysis 
 
Transfer buffer (5x)  250 mM Tris-HCl, pH 8.6 
     1.92 M glycin 
 
Transfer buffer (1x)  20 % (v/v) 5x blotting buffer 
     10 % (v/v) methanol 
 
TBS     10mM Tris/HCl pH 7.5   
     150mM NaCl 
 
TBS-T    10mM Tris pH 8 
     150mM NaCl 
     0.1% (v/v) Tween-20 
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ECL solution A  Uplight HRP blot Reagent A (UP99619A-A), luminal/enhancer 
    solution, Uptima Interchim 
 
ECL solution B  Uplight HRP blot Reagent B (UP99619A-B), oxidizer solution, 
    Uptima Interchim 
 
4.1.3 Antibodies 
 
Anti-PARP1   rabbit, immunization of rabbit made at UZH 
 
Anti-PAR (LP96-10)  rabbit, alexis biosience, 210-890-R100   
Anti-Tubulin   mouse, Sigma, T6199 
Anti-GAPDH (FL-335) rabbit, Santa-Cruz, sc25778 
 
Secondary antibodies: 
Anti-rabbit   ECL TM Anti-rabbit IgG, horseradish Peroxidase linked whole 
    antibody (from donky), NA934V, GE Healthcare UK Limited 
 
Anti-mouse   ECL TM Anti-mouse IgG, horseradish Peroxidase linked whole 
    antibody (from sheep), NA931V, GE Healthcare UK Limited 
 
4.1.4 Kits and enzymes 
 
RNA isolation   Agilent Total RNA Isolation Mini Kit, Agilent Technologies 
 
Reverse transcriptions High Capacity cDNA reverse Transcription Kit,  
     Applied Biosystems 
 
RT-PCR   GoTag polymerase, Promega 
 
Syber Green   Sensi MixTM Plus SYBR®, Quantace 
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4.1.5 Chemicals 
 
Stimulation 
 
LPS     LPS (Lipopolysaccharides) from Escherichia coli055:B5  
    (Sigma, L2880) was used. The LPS powder was aliquoted in 
    5mg/ml in PBS in Eppendorf tubes and stored at -20°C. 
 
TNF-α    Recombinant TNF-α was produced in the own laboratory. 
 
 
Cell synchronization 
 
Thymidine   99-100%, Sigma-Aldrich, T1895 
 
Aphidicolin   from Nigrospora sphaerica, minimum 98%, Sigma-Aldrich, 
    A0781, liquid Aphidicolin was aliquoted in 5mg/ml in DMSO. 
 
Nocodazol   ≥99% (TLC), powder, Sigma-Aldrich, M1404 
 
 
DNA staining FACS preparation 
 
Propidium Iodid  Propidium Iodide solution, 1mg/ml in water, Sigma-Aldrich, 
    P4864 
 
RNase    RNase A, from bovine pancreas, Roche, 10 109 169 001 
 
 
4.1.6 Primer 
 The primers were designed using several programs from the internet. The sequence of 
the gene was taken from the Genbank (http://www.ncbi.nlm.nih.gov/). The exon and intron 
informations were taken from (http://www.ensembl.org/index.html). Primers were self 
designed or suggested by the primer request program 
(http://eu.idtdna.com/Scitools/Applications/PrimerQuest/Default.aspx/?c=EU) and then the 
primer sequences were analysed using primer analyse programs 
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(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/) and oligocalc 
(http://www.basic.northwestern.edu/biotools/oligocalc.html).  
 Forward and reverse primers would bind to 2 different exons with an intron in 
between, typically larger than 3kb. Even better, the primers would cover an exon-exon 
boundary. The primers were designed such that their annealing temperature was about 60°C 
and with a 100-200 bp product. The difference in annealing temperature between forward and 
reverse primer was never larger than 1°C. The GC content was between 40 and 60 %. Never 
more than 2 or 3 G/C were at the 3’end and runs of the same nt were avoided. In order to 
minimize self-dimer and hetero-dimer (primer-dimer) formation, the delta G of primer dimers 
was never smaller than -6kcal/mol. The secondary structure of the template was checked with 
the mfold program (http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/dna-form1.cgi) 
and hairpins were avoided. 
 Primers were ordered from Sigma-Aldrich and first a control run with RNA dilutions 
from 1 to 1: 10 000 in 10fold steps was done and afterwards an agarose gel was run with the 
qRT-PCR products to confirm the amplification of only 1 PCR product. The usefulness was 
defined on the basis of the melting curve and the agarose gel results.  
 
Primers were ordered from Sigma-Aldrich. 
Forward sequence Gene 
Reverse sequence 
5’-GAAGAAGAGCCCATCCTCTGTG-3’ IL-1b 
5’-GCTCATGGAGAATATCACTTGTTGG-3’ 
5’-CAACATCAAGAGCAGTAGCAGTTCC-3’ IL-12b 
5’-CAGGTGACATCCTCCTGGCAG-3’ 
5’-GACAGTGACTTTCATCCCAGTTGC-3’ IL-15 
5’-GCAGCCAGATTCTGCTACATTCTTG-3’ 
5’-GTCGTAGCAAACCACCAAGTGG-3’ TNF alpha 
5’-GAGATAGCAAATCGGCTGACGG-3’ 
5’-CTCATTGGCATGGAAGGAAATGTGAC-3’ Hif1an 
5’-TGTCAAAGTCCACCTGGCTCTG-3’ 
5’-GCACGAACTTAACCACCATCTTCC-3’ IP-10 
5’-CTACCCATTGATACATACTTGATGACAC-3’ 
Mpa2l 5’-GATGCTGAAGAAGCTAATGAAGGATC-3’ 
Material and Methods 
 
 
54 
 5’-CCTTGATGACATCTCTCAGTTGCTG-3’ 
5’-CCATAGATGCAGCAAGGAGA-3’ Lif 
5’-CAGTCCTGAGATGAGCCTGA-3’ 
5’-ACATGCCTGTCACGTTGAAT-3’ Csf2 
5’-TTGAGTTTGGTGAAATTGCC-3’ 
5’-GCAGTCACCCATGTTCGATGG-3’ PARP1 
5’-GCTTCTCTGGATCCACCATC-3’ 
5’-GCTACACTGAGGACCAGGTTG-3’ GAPDH 
5’-GCCCCTCCTGTTATTATGGGGG-3’ 
5’-CCTAACAGGATGCTGCTCTGG-3’ PARP2 
5’-GCTACCTCTGACAGAAGAAGC-3’ 
 
4.2 Methods 
4.2.1 Culturing of cells 
 Cell culture work was performed under a sterile hood. Cells were cultured as adherent 
monolayer on 10 cm cell culture dishes. Cells were growm in a cell incubator at 37 °C and 
5% CO2. 
 To split cells, old medium was aspirated and cells were washed once with 10 ml PBS 
for 10 seconds. After aspirating the PBS, 3 ml new medium was added. Cells were scraped 
off the plate using a cell scraper, and resuspended in the medium by pipetting them 5 times 
slowely up and down. Finally, 1ml was transferred to a new dish, which was prepared with 10 
ml new medium. To determine the exact cell numbers, cells were counted in the Neubauer-
counting chamber. 
 
4.2.2 Freezing of cells 
 Cells from a 80% confluent 10cm dish (corresponding to approximately 5 x 106 cells) 
were washed once with 10 ml PBS. 1ml DMSO-FCS solution (10% DMSO, 90% FCS) was 
added to the cells, which were subsequently scraped off the plate and resuspended by 
pipetting them 5 times. Then they were transferred to a cryo-vial. The vial was first stored for 
one night at -80°C in a cryo-box with isopropanol and afterwards stored in liquid nitrogen. 
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4.2.3 Thawing of cells 
 Cryo-vial were thawed in a 37°C water bath. As soon as the whole ice was thaw, the 
cells were transferred in a prepared 15ml Falcon tube with 5 ml warm medium. After spinning 
down for 3 minutes at 1000rpm, the cell pellet was dissolved in 1 ml medium and transferred 
in a new 10cm dish prepared with 10 ml fresh medium. The following day, the medium 
(containing 10% FCS) was changed. 
 
4.2.4 Stimulation of cells with LPS/TNF-α  
 LPS (10µg/ml) or TNF-α (100ng/ml) was directly added in the medium. The dish was 
holded transversely and then carefully shaked. 
 
4.2.5 Cell synchronization 
 To synchronize cells, 1.5 x106 cells/ml were seeded in a 10 cm dish and incubated for 
24h at 37°C and 5% CO2. After 24h the cells were adherent and approximately at 40 - 50% 
confluence. After washing with 10 ml PBS, 6 ml new medium containing the according 
synchronization compound was added. After the chosen duration with the synchronization 
compound in the incubator and after the LPS stimulation (description see above), cells were 
prepared for FACS analysis, protein or RNA isolation. 
 
Attached time protocols were followed for each experiment:  
 
For Aphidicolin  
First day: 6–7 PM, seeding of total 1.5 x106 cells 
Second day: 7 PM, Aphidicolin application (5µg/ml), 14h block 
Third day: 8 AM, LPS stimulation, cells fixed for first control by FACS 
  9 AM, RNA isolation, cells fixed for second control by FACS, protein isolated 
   (only shMock cells) 
 
For Nocodazol  
First day: 5-6 PM, seeding of total 1.5 x106 cells 
Second day: 6 PM, Nocodazol application (0.4µg/ml), 15h block 
Third day: 8 AM, LPS stimulation, cells fixed for first control by FACS 
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  9 AM, RNA isolation, cells fixed for second control by FACS, protein isolated 
   (only shMock cells) 
 
For Thymidine 
First day: 5-6 PM, seeding of total 1.5 x106 cells 
Second day: 6 PM, thymidine application (0.6mg/ml), 15h block 
Third day: 8 AM, LPS stimulation, cells fixed for FACS analysis 
  9 AM, RNA isolation, cells fixed for FACS analysis, protein isolated (only 
   shMock cells) 
 
For Thymidine with 3 hours release: 
First day: 5-6 PM, seeding of total 1.5 x106 cells 
Second day: 6 PM, thymidine application (0.6mg/ml), 15h block 
Third day: 8 AM, wash 3 times with 10ml PBS, new Medium without thymidine 
  10 AM, LPS stimulation, cells fixed for FACS analysis 
  11 AM, RNA isolation, cells fixed for FACS analysis, protein isolated (only 
   shMock cells) 
 
4.2.6 DNA staining with Propidium Iodide 
 For adherent cells the medium from a 40 - 50% confluent 10 cm dish (containing 
approximately 2× 106 cells) was aspirated and the cells were trypsinized with 1.5 ml trypsin 
on the plate for 5 minutes. Swimming cells were first spun down for 3 minutes at 1100rpm. 
The medium was aspirated and the cell pellet was subsequently dissolved with 1ml trypsin for 
30 seconds. The trypsin-cell-mixture was transferred in a FACS tube containing 3ml Medium  
to inactivate the Trypsin. Cells were spun down for 3 minutes at 1100 rpm by 4°C, afterwards 
the cell pellet was washed with 2 ml cold PBS and again spun down for 3 minutes at 1100rpm 
at 4°C. After aspirating PBS, the cell pellet was very well dissolved in 300µl cold PBS. Cells 
were fixed in 70% ethanol by adding during vortexing drop by drop 700µl 100% Ethanol (-
20°C). For complete fixation, FACS tubes were left for 30 minutes on ice. Or cells could be 
stored up to 1 week at 4°C. Fixed cells were spun down for 5 minutes at 1200rpm at 4°C, the 
supernatant containing 70% ethanol was discarded, and the cell pellet was dissolved in 2 ml 
cold PBS before an additional round of centrifugation for 5 minutes at 1200 rpm at 4°C. 
During this time the Promidium Iodide (PI) Staining Solution was prepared by solving 
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100µg/ml RNase A and 20µl/ml PI in cold PBS (for 10 samples take 5 ml cold PBS, 250 µl 
Rnase A (2mg/ml) and 100ul PI (1mg/ml)). After discarding PBS, 500 µl of the Staining 
Solution with RNase was used to dissolve the cell pellet. For a good DNA staining, cells were 
incubated in the dark for 30 minutes at 37°C. FACS analysis was performed immediately, 
although cells could also be stored for one week at 4°C. 
 
4.2.7 FACS Analysis 
 FACS analysis was performed according to the manufactured protocol. The DNA 
histograms representing the fluorescence intensity distribution among cells indicate the 
number of cells per channel in the ordinate and the relative fluorescence intensity which 
varies in proportion with the DNA content in the abscissa. To facilitate the comparison 
between different samples in a given figure, the scale of the ordinate was normalized to a 
predetermined height of 1000 or 1500, if it was useful. For each analysis 100 000 cells were 
counted. 
 
4.2.8 Generation of whole cell extracts 
 The medium was aspirated and the cells were washed with 10 ml PBS. 3 ml of fresh 
medium were added to scrape the cells off the plate by using a cell scraper. The cells were 
collected in a 15ml Falcon tube and spun down for 3 minutes at 1100 rpm at 4°C.  The 
supernatant was discarded and the cell pellet was washed with 2ml cold PBS. After repeating 
the centrifugation for 3 minutes at 1100 rpm, 4°C, the cell pellet was resuspended in 1ml cold 
PBS and the cells were transferred in an eppendorf tube. After spinning down for 3 minutes, 
at 1100 rpm, at 4°C, the supernatant was aspirated and if preferred, the cell pellet was snap-
freezed in liquid nitrogen and stored at -20°C. If proteins were isolated immediately, 100 -
200µl (dependent on the cell pellet size) lysis buffer were added to the cells and the tube was 
rolled for 30 minutes at 4°C. After centrifugation of the extract for 30 minutes, at 14 000 rpm 
and at 4°, proteins, which were now in the supernatant, were transferred in a new eppendorf 
tube. 
 
 
 
Material and Methods 
 
 
58 
4.2.9 Bradford Protein Assay 
 The Bradford protein assay is a spectroscopic analytical procedure used to measure the 
concentration of protein in a solution. Bradford is a dye, which stains all proteins with equal 
intensity. The total protein amount is measured. The Bradford Solution (5x) was diluted 5 
times with ddH2O to the desired amount. The standard curve was measured by adding 20 µl 
of the standard proteins (0.2 mg/ml, 0.36 mg/ml, 0.54 mg/ml and 0.72 mg/ml) to 1ml 1x 
Bradford Solution. To measure protein of the whole cell extract, 2 µl (or more if needed, the 
color should at least reach the level from the lowest standard solution) of the extract were 
mixed with 1ml 1x Bradford Solution. The absorbance was measured at 595nm and the 
protein concentration of the extract was calculated with help of the standard proteins. 
 
4.2.10 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Separation of proteins from a protein mixture by their molecular mass was achieved 
by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE). The anionic 
detergent SDS denatures proteins and forms negatively charged complexes with constant 
charge to mass ratios. In an electric field, proteins complexed by SDS migrate according to 
their charge allowing the separation by molecular weight. Two glass slides (10 x 8.5 cm) were 
rinsed with deionized water and two distance holders (10 x 0.15 cm) were placed in between 
them. The slides were put into a gel preparation electrophoresis unit. 8 ml of the separating 
gel solution were poured between the glass slides and mounted with 70 % (v/v) ethanol. Upon 
polymerisis of the polyacrylamide gel, the alcohol was removed and the upper border of the 
separating gel was rinsed several times with deionized water. The stacking gel solution was 
poured onto the separating gel and a comb with 10 wide or 15 narrow slots was inserted to 
generate the sample pockets. Polymerized gels could be stored in a wet chamber at 4 °C for 
up to 3 days. 
 Before separation, protein samples were adjusted to equal volumes with H2O, 10x 
protein loading buffer was added to the samples before they were heated at 95 °C for 5 
minutes. The gel chamber of the electrophoresis unit was filled with 1x running buffer, the 
sample pockets were rinsed with running buffer and samples were loaded into the pockets. 4 
µl of a prestained molecular weight marker were loaded in one pocket to follow the separation 
of the proteins and to control the transfer efficiency of proteins onto nitrocellulose or PVDF 
membranes upon blotting (see western blot). Samples were allowed to enter the stacking gel 
at a constant voltage of 80V. When the loading dye front reached the separating gel, the 
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voltage was increased to 100V. Electrophoresis was typically stopped when the loading dye 
front had reached the bottom of the gel. After electrophoresis, the gel was removed from the 
glass slides, the stacking gel was peeled off and proteins in the separating gel were transferred 
onto a nitrocellulose or PVDF membrane by western blot. 
 
4.2.11 Western Blot analysis 
 Proteins were separated on a SDS-Gel electrophoresis and electroblotted over night at 
30 V onto a nitrocellulose or PVDF membrane in transfer buffer at 4°C. One hour before 
terminating the voltage was increased to 100 V. The western blot “sandwich” was assembled 
as followed: black plastic, one sponge wetted in the transfer buffer, 2 filter papers wetted in 
the transfer buffer, SDS-gel, nitrocellulose or PVDF membrane (the PVDF membrane has 
first to be activated in 100% methanol for 20 seconds and washed for 1 minute in the transfer 
buffer; the nitrocellulose membrane on the other hand has only to be wetted for 5 seconds 
with transfer buffer), 2 filter papers wetted in the transfer buffer, one sponge wetted in the 
transfer buffer, white or clear plastic. During the sandwich assembly air bubbles between the 
gel and the membrane were carefully removed by rolling a glass rod over the assembled 
sandwich. The sandwich was inserted into a western blot chamber, which was cooled with an 
ice block. The following morning the blotting was completed, the membrane was removed 
from the blotting chamber and washed in deionized water. 
 After blocking the membranes for 60 min in TBS-T containing 5% (w/v) milk powder, 
the membranes were incubated with the appropriate antibodies, diluted in TBS-T with 5% 
(w/v) milk powder, for 2 hours at room temperature. Then the membranes were washed 3 
times for 10 minutes in TBS-T and incubated with the corresponding secondary antibodies, 
diluted in TBS-T with 5% (w/v) milk powder, for 1 hour. The membranes were subsequently 
washed 2 times for 10 minutes in TBS-T and additionally 2 times for 10 minutes in TBS. All 
washing and incubation steps for immunodetection of proteins were conducted on a shaker at 
room temperature. The membrane was placed on a sarasin transparent sheet and 1 ml of ECL 
solution (1 ml ECL solution A, 1 drop ECL solution B) were dropped directly onto the 
membrane. The membrane was exposed to a x-ray film for different time points in the dark 
before chemiluminescence was detected using a chemiluminescence imager. Exposure times 
were typically chosen in the range of 1 second to 15 minutes. 
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4.2.12 RNA Isolation 
 RNA was isolated directly from cells on plate with the RNA Isolation Kit (Agilent 
Technologies). To be able to use 600 µl lysis solution for 2 to 3 dishes, it was important, to 
aspirate the remaining PBS completely, otherwise PBS would interfere with efficient cell 
lysis. For the further RNA isolation steps the manufactured protocol was followed. To keep 
RNA after isolation, the samples were snap freezed and stored at -80°C. 
 
4.2.13 Quantification of RNA 
 RNA was quantified with the NanoDrop spectrophotometer. After blanking and 
setting the system to zero with 1 µl of destilled water, 1 µl of RNA-sample was placed onto 
the sensor and the RNA concentration was automatically measured and calulated by the 
instrument. The NanoDrop ND-1000 Spectrophosphometer (260/280nm) measures 1µl 
samples with concentrations between 2 ng/µl and 3000 ng/µl. 
 
4.2.14 Reverse Transcription 
 Reverse transcription was performed with the High Capacity cDNA, Reverse 
Transcription Kit (Applied Biosystems). To 2 µg isolated RNA different amount of destilled 
H2O was added (up to 10µl). Subsequently, 10µl of the Master Mix were added, to get a total 
reaction volume of 20µl. All preparations were done one ice. 
 
Master Mix for 1 sample contained:   
 
 
 
 
 
 
 
 
 
 
2µl   10x RT buffer 
0.8µl   25x dNTPs 
2µl   10x Primers 
1µl   reverse transcriptase (add not until use
  immediately) 
4.2 µl  destilled H2O 
------------------------------------------------------------------ 
10µl  total volume 
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 For the negative reverse transcriptase control (-RT), a Master mix without RT was 
pipetted. Reverse Transcription was performed in a GeneAmp PCR System 2700 (Applied 
Biosystems). PCR protocol was: 
 
 
 
 
Newly transcribed cDNA was stored at -20°C. 
 
4.2.15 Conventional RT-PCR 
 Conventional RT-PCR included the previous transcribed cDNA (see above). For a 
standard PCR, GoTag polymerase (Promega) and self designed primers were used. 
 
GoTag PCR Master Mix: 
 
 
 
 
 
 
 
 All manipulations were performed on ice. 1.5µl of cDNA were pipetted in each PCR 
tube. Then, GoTag polymerase was added to the Master Mix, which was carefully mixed. 
23.5µl from the Master Mix were added to each sample. The total reaction volume was 25µl. 
 
The PCR runs were performed using the GeneAmp PCR Systems (Applied Biosystems). 
 
Protocol for PCR: 
 
 
 
 
The different samples were subsequently analyzed by Agarose Gel electrophoresis (see 2.2.4) 
10 minutes  25°C 
120 minutes  37°C 
5 seconds  85°C 
∞   4°C 
14.68 µl ddH20 
5µl  GoTagBuffer 
1.5µl  GoTag MgCl2 
0.2µl  dNTPs (25mM) 
0.12µl  GoTag (polymerase) 
1µl  forward primer (10µM) 
1µl  reverse primer (10µM) 
23.5µ l  total volume 
1.5 µl  cDNA       
25µ l  total volume 
 
 
2’ 95°C 
30’’ 95°C  
30’’ 55°C  25 cycles 
1’ 72°C 
7’ 72°C 
∞ 4°C 
Material and Methods 
 
 
62 
4.2.16 qRT-PCR 
 qRT-PCR was performed using SensiMix Plus SYBR Green reaction mix. Each 
sample contained approx. 10 ng cDNA dependent on how much cDNA was available. It is 
important, that every sample contained always the same amounts of cDNA. The sample 
volume was in the end 10 µl, of which 5.8µl were the Syber Green Primer master mix and 4.2 
µl were the cDNA dilution.  
 
  cDNA dilution: 
 
 
 
 
 
The original cDNA have to be diluted, that in 4.2µl are approx. 10ng cDNA.  
Syber Green Master mix for 1 sample: 
 
 
 
 
 In each run 4 additional samples, called “standard dilutions”, containing different 
dilutions of the cDNA (total cDNA amount: 20ng, 2ng, 0.2ng and 0.02ng) were included. 
These standard dilution values are indicated for each analysed gene and are used by the qRT-
PCR machine to calculate the results of the samples. A “no template” control only containing 
nuclease free water and the “–RT” sample were included in each run. When all cDNA 
dilutions and Syber Green Primer Master mix were prepared, the cDNA was first equally 
distributed into the qPCR tubes (4.2µl in each tube) and then 5.8µl of the Syber Green Primer 
Master mix were added. All preparation was done one ice using the 72-well PCR plate. The 
PCR run was performed in the Rotor Gene (RG-300A) from Rcorbett Research and the 
manufactered instructions were followed.  
 
Procedure of PCR: 
 
 
 
5 µl  DNA (100ng/µl) 
195 µl ddH2O 
200 µl total volume 
→from this 4.2 µl (10.5ng DNA) in each sample 
Initial incubation 10 minutes 95°C 
Denature  20 seconds 95°C 
Annealing  30 seconds 60°C  40 cycles 
Elongation  30 seconds 72°C 
Melting curve  heating up from 60-99°C 
5 µl  Syber Green 
0.4 µl Forward primer (4µM) 
0.4 µl Reverse primer (4µM) 
5.8 µl total volume 
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 The fluorescence data were collected automatically after each cycle. A melt curve was 
calculated in the end by heating the samples from 60 to 99°C. The fluorescence data were 
analyzed by the Rotor-Gene computer program.   
 
4.2.17 Agarose Gel electrophoresis 
 To analyze DNA samples after PCR reactions, agarose gel electrophoresis was 
performed. At physiological pH, DNA is an acidic molecule with each nucleotide carrying 
one negative charge at its phosphate group. For the separation of DNA fragments between 1 
kbp and 10 kbp, a 1.5 % (w/v) agarose solution in 1x TAE buffer (70 ml for a small gel and 
140 ml for a big gel) was prepared and heated in a microwave oven until the solution started 
to boil. Afterwards, the liquid agarose solution was poured into a gel tray in the cold room 
(4°C) and 5–10 µl ethidium bromide were added to the agarose solution. Ethidium bromide 
intercalates with doublestranded DNA and fluoresces when excised at 302 nm. A comb was 
inserted into the gel to form the sample pockets. After the gel had completely solidified, it 
was transferred into the electrophoresis unit and covered with 1x TAE buffer. The comb was 
removed and DNA samples, to which a tenth part of 10x DNA loading buffer was previously 
added, were loaded. A DNA marker was also loaded to one of the sample pockets as control. 
Typically, Phage lambda DNA digested with Pst, containing fragments from 250 to 10,000 
base pairs, was used as marker. 5-10 µl ethidium bromide solution were added into 1x TAE 
buffer in the tank. Samples were allowed to enter the gel at a constant voltage of 80 V for 15 
minutes. The voltage was then increased to 120 V and gels were run for another 20 minutes 
before being removed from the gel tray. The interaction of ethidium bromide with 
doublestranded DNA allowed the detection of DNA under UV light. 
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